Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy

Effect of Nursing Method of Psychological Intervention Combined with Health Education on Lung Cancer Patients Undergoing Chemotherapy

At present, lung cancer has become clinically the malignant tumor with the highest incidence and mortality rate in China. Smoking, environmental pollution, infection, etc., are closely related to lung cancer. To investigate the effect of the nursing method of psychological intervention combined with health education on lung cancer patients undergoing chemotherapy, 70 lung cancer patients who received chemotherapy in our hospital from June 2017 to June 2020 were selected and randomly divided into a routine intervention group (n = 35) and a combined intervention group (n = 35). Patients in the two groups had the same chemotherapy method and medication. The routine intervention group received the routine nursing intervention, while on this basis, the combined intervention group received psychological intervention combined with health education. After 6-week nursing, self-rating anxiety scale (SAS) score, self-rating depression scale (SDS) score, cancer pain score before and after nursing, improvement of respiratory function before and after nursing, sleep quality score, quality of life score, and nursing satisfaction were analyzed. Through nursing intervention, the quality of life indexes such as physiological, physical, social, emotional, and other indexes in the combined intervention group were significantly better than those in the routine intervention group, with statistical differences (P < 0.01). The nursing satisfaction in the combined intervention group was significantly better than that in the routine intervention group, with statistical significance (χ² = 8.9342, P < 0.05). The psychological intervention combined with health education for lung cancer patients undergoing chemotherapy can effectively alleviate anxiety and depression, increase confidence in treatment, reduce pain and significantly improve sleep quality, respiratory function, quality of life, and nursing satisfaction.

The efficacy and safety of immune checkpoint inhibitor in patients with relapsed small-cell lung cancer: A systematic review and meta-analysis

WHAT IS KNOWN AND OBJECTIVE

Immune checkpoint inhibitors (ICIs) have been approved for treating small-cell lung cancer (SCLC). However, the efficacy and safety profile of ICIs for relapsed SCLC remains under investigation. In this study, we assessed the efficacy and safety of ICIs in the treatment of relapsed SCLC patients.

METHODS

The databases, including Pubmed, Embase, and the Cochrane library, were systematically searched to retrieve potential eligible studies from the establishment of the database to May 2021. The primary outcomes were survival, treatment responses, and safety. Randomized controlled trials and real-world studies that met the inclusion criteria were included. The RevMan 5.4 and R software were used for meta-analysis.

RESULTS AND DISCUSSION

A total of eight articles involving 653 patients was included. Meta-analyses results showed that the overall response rate (objective response rate [ORR]) of the ICIs group was 0.12 (95% confidence interval [CI]: 0.07-0.18). The median overall survival was 7.97 (95% CI: 5.94-9.47) months, while the progression-free survival was 1.70 (95% CI: 1.40-2.28) months. Although chemotherapy showed a favourable ORR (odds ratio [OR] = 0.74; 95% CI: 0.39-1.41; p = 0.36) and a significantly better disease control rate (OR = 0.28; 95% CI: 0.11-0.70; p = 0.007), patients treated with ICIs had a reduced risk of mortality (hazard ratio = 0.87; 95% CI: 0.73-1.03; p = 0.10). With regards to adverse events (AEs), the rates of any AEs and ≥grade 3 AEs were 0.56 (95% CI: 0.52-0.60) and 0.13 (95%CI: 0.06-0.20), respectively.

WHAT IS NEW AND CONCLUSION

For relapsed SCLC patients, the administration of ICIs resulted in a similar survival outcome and acceptable safety compared with chemotherapy. Further studies are needed to explore potential biomarkers for relapsed SCLC patients who may benefit from immunotherapy.